Type of security: Stock
Sector: Health Care
The data is delayed by 15 minutes.
AXGN is in the long-term up 469% in 7 years.
Description: AxoGen, Inc. operates as a medical technology company. It focuses on advancing the science and commercialization of peripheral nerve repair solutions. It offers a range of surgical nerve repair solutions, including Avance Nerve Graft, a processed nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa ExtraCellular Matrix (ECM) coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product used to wrap and protect injured peripheral nerves and reinforce coaptation sites while preventing soft tissue attachments. The company?s products are used by plastic reconstructive surgeons, and orthopedic and plastic surgeons during surgical interventions to repair various nerve injuries. It procures and processes its tissue products in the United States, Canada, Italy, Austria, the United Kingdom, the Netherlands, Israel, and Switzerland. AxoGen, Inc. is headquartered
|Shares Outstanding||EPS||EPS Growth - 4 Quarters||EPS Growth - Q/Q|
|EPS Growth - Y/Y||Sales Growth - 4 Quarters||17.49%||Sales Growth - Q/Q||3.27%||P/E|
|P/E To EPS Growth||P/S||P/BV||Price/Cash Per Share|
|Price/Free Cash Flow||ROA||-60.58%||ROE||2506.62%||ROI|
|Current Ratio||7.57||Quick Ratio||6.6||Long Term Debt/Equity||1.12||Debt Ratio||-5.05|
|Gross Margin||80.01%||Operating Margin||-50.21%||Net Profit Margin||-91.49%||Dividend Payout Ratio|
|Cash From Financing Activities||Cash From Investing Activities||13.59 M||Cash From Operating Activities||-40 K||Gross Profit||3.97 M|
|Net Profit||-2.51 M||Operating Profit||-2.54 M||Total Assets||28.14 M||Total Current Assets||26.02 M|
|Total Current Liabilities||3.44 M||Total Debt||25.27 M||Total Liabilities||28.82 M||Total Revenue||4.95 M|
|High 52 week||55.9||Low 52 week||14.62||Last close||14.62||Last change||-11.98%|
|RSI||34.8||Average true range||1.7||Beta||0.31||Volume||57.96 K|
|Simple moving average 20 days||-18.76%||Simple moving average 50 days||-44.83%||Simple moving average 200 days||-61.88%|
|Performance Week||-5.86%||Performance Month||-48.88%||Performance Quart||-57.72%||Performance Half||-71.33%|
|Performance Year||-47.32%||Performance Year-to-date||-28.44%||Volatility daily||8.98%||Volatility weekly||20.07%|
|Volatility monthly||41.13%||Volatility yearly||142.48%||Relative Volume||176.98%||Average Volume||814.29 K|
|New High||New Low|
2019-09-20 10:38:00 | Why AxoGen, Inc.'s NASDAQ:AXGN CEO Pay Matters To You
2019-09-19 07:00:00 | Axogen, Inc. to Present at the Cantor Fitzgerald Global Healthcare Conference
2019-09-11 20:00:00 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Mammoth Energy, Acer Therapeutics, Realogy Holdings, and AxoGen and Encourages Investors to Contact the Firm
2019-08-18 17:59:18 | Weekly CEO Buys Highlight
2019-08-14 21:02:29 | Bragar Eagel & Squire is Investigating Certain Officers and Directors of Lannett, Molson Coors, AxoGen, and American Renal Associates and Encourages Investors to Contact the Firm
2019-08-12 10:15:02 | Axogen Inc AXGN CEO Karen L. Zaderej Bought $1 million of Shares
2019-08-07 05:04:11 | Edited Transcript of AXGN earnings conference call or presentation 6-Aug-19 8:30pm GMT
2019-08-06 20:24:22 | AxoGen Inc AXGN Q2 2019 Earnings Call Transcript
2019-08-06 18:55:10 | AxoGen AXGN Reports Q2 Loss, Misses Revenue Estimates
2019-08-06 14:11:53 | Does AxoGen NASDAQ:AXGN Have A Healthy Balance Sheet?
2019-07-30 10:38:02 | Earnings Preview: AxoGen AXGN Q2 Earnings Expected to Decline
2019-07-29 07:00:00 | Axogen, Inc. to Participate at Canaccord Genuity 39th Annual Growth Conference
2019-06-18 14:40:02 | Have Insiders Been Selling AxoGen, Inc. NASDAQ:AXGN Shares This Year?
2019-06-14 16:38:29 | Here’s What Hedge Funds Think About AxoGen, Inc. AXGN
2019-05-23 07:00:00 | Axogen, Inc. to Participate at Upcoming Investor Conferences
2019-05-09 01:34:56 | Edited Transcript of AXGN earnings conference call or presentation 8-May-19 8:30pm GMT
2019-05-09 00:23:47 | AxoGen Inc AXGN Q1 2019 Earnings Call Transcript
2019-05-08 17:45:09 | AxoGen AXGN Reports Q1 Loss, Tops Revenue Estimates
2019-05-08 16:41:23 | AxoGen: 1Q Earnings Snapshot
2019-05-08 16:01:00 | Axogen, Inc. Reports 2019 First Quarter Financial Results
2019-05-04 21:39:09 | Here’s What Hedge Funds Think About AxoGen, Inc. AXGN
2019-05-02 07:00:00 | Axogen, Inc. Appoints New Members to Board of Directors
2019-05-01 10:32:02 | Analysts Estimate AxoGen AXGN to Report a Decline in Earnings: What to Look Out for
2019-04-16 15:28:59 | Is There An Opportunity With AxoGen, Inc.'s NASDAQ:AXGN 48% Undervaluation?
2019-03-22 18:26:00 | Lifshitz & Miller LLP Announces Investigation of 22nd Century Group, Activision Blizzard, Inc., Astec Industries, Inc., Avon Products, Inc., Axogen, Inc., Everquote Inc. and Health Insurance Innovations, Inc.
2019-03-20 11:54:00 | Robbins Arroyo LLP: AxoGen, Inc. AXGN Misled Shareholders According to Class Action
2019-03-11 10:44:00 | FINAL DEADLINE - AXGN AxoGen, Inc. - Bronstein, Gewirtz & Grossman, LLC
2019-03-10 22:50:00 | AXOGEN 24 HOUR DEADLINE ALERT: Approximately 24 Hours Remain; ClaimsFiler Reminds Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against AxoGen, Inc. - AXGN
2019-03-08 22:50:00 | AXOGEN 72 HOUR DEADLINE ALERT: Approximately 72 Hours Remain; Former Louisiana Attorney General and Kahn Swick & Foti, LLC Remind Investors with Losses in Excess of $100,000 of Deadline in Class Action Lawsuit against AxoGen, Inc. - AXGN
2019-03-08 21:30:22 | DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against AxoGen, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
2019-03-08 13:13:37 | What Should We Expect From AxoGen, Inc.’s NASDAQ:AXGN Earnings Over The Next Few Years?